1. Home
  2. EFSC vs MESO Comparison

EFSC vs MESO Comparison

Compare EFSC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enterprise Financial Services Corporation

EFSC

Enterprise Financial Services Corporation

HOLD

Current Price

$65.84

Market Cap

2.2B

Sector

Finance

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$13.15

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EFSC
MESO
Founded
1988
2004
Country
United States
Australia
Employees
1418
81
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
EFSC
MESO
Price
$65.84
$13.15
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$66.33
N/A
AVG Volume (30 Days)
220.0K
151.7K
Earning Date
04-22-2026
02-26-2026
Dividend Yield
2.36%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.22
$629.74
Revenue Next Year
$3.77
$30.65
P/E Ratio
$11.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.18
$10.32
52 Week High
$66.18
$21.50

Technical Indicators

Market Signals
Indicator
EFSC
MESO
Relative Strength Index (RSI) 69.45 38.09
Support Level $52.48 N/A
Resistance Level N/A $16.11
Average True Range (ATR) 1.38 0.45
MACD 0.26 0.02
Stochastic Oscillator 84.02 2.65

Price Performance

Historical Comparison
EFSC
MESO

About EFSC Enterprise Financial Services Corporation

Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Its Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: